Reiss-Clark Cindy
SEC CIK 1916513 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| WST | West Pharmaceutical Services | SVP | 5,047 | — | $1.37M | 6 | 2023-02-21 | 2025-02-18 |
Most active insiders at WST, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Favorite Annette F | SVP, Chief HR Off | — | $6.30M |
| 2 | Winters Chad | VP, CAO | — | $269.4K |
| 3 | Poussot Rodolphe Jean | SVP, Strategy, Corp. Dev | — | — |
| 4 | Campbell Shane Alden | SVP, Proprietary Segment | — | — |
| 5 | Lockhart Stephen H | Dir | — | — |
| 6 | Witherspoon Charles | VP, Treas | — | — |
| 7 | Joseph Molly | Dir | — | — |
| 8 | McMahon Robert W. | SVP, CFO | — | — |
| 9 | Feehery William F | Dir | — | — |
| 10 | Pucci Paolo | Dir | — | — |
Reiss-Clark Cindy made no open-market trades at WST in the last 12 months.
Transactions 6
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-20 | 2025-02-18 | WST | West Pharmaceutical Services | Reiss-Clark Cindy | Chief Commercial Off | F - Tax | $211.00 | -83.18 | 5,047 | -2% | -$17.6K |
| D | 2025-02-20 | 2025-02-18 | WST | West Pharmaceutical Services | Reiss-Clark Cindy | Chief Commercial Off | M - OptEx | $211.00 | +246.16 | 5,131 | +5% | +$51.9K |
| D | 2024-02-22 | 2024-02-20 | WST | West Pharmaceutical Services | Reiss-Clark Cindy | Chief Commercial Off | A - Grant | $0.00 | +551 | 4,884 | +13% | $0 |
| D | 2023-08-24 | 2023-08-22 | WST | West Pharmaceutical Services | Reiss-Clark Cindy | Chief Commercial Off | S - Sale+OE | $393.34 | -3,477 | 4,320 | -45% | -$1.37M |
| DM | 2023-08-24 | 2023-08-22 | WST | West Pharmaceutical Services | Reiss-Clark Cindy | Chief Commercial Off | M - OptEx | $263.16 | +3,477 | 7,020 | +98% | +$915.0K |
| D | 2023-02-23 | 2023-02-21 | WST | West Pharmaceutical Services | Reiss-Clark Cindy | SVP | A - Grant | $306.68 | +970 | 4,320 | +29% | +$297.5K |
Purchase Sale Sale after option exercise All abbreviations